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Abstract: Background: A member of the Trk family of neurotrophin receptors, tropomyosin
receptor kinase B (TrkB, encoded by the NTRK2 gene) is an increasingly important
target in various cancer types, including glioblastoma (GBM). EGFR is among the most
frequently altered oncogenes in GBM, and EGFR inhibition has been tested as an
experimental therapy. Functional interactions between EGFR and TrkB have been
demonstrated. In the present study, we investigated the role of TrkB and EGFR, and
their interactions, in GBM.
Methods and Results: Analyses of NTRK2 and EGFR gene expression from The
Cancer Genome Atlas (TCGA) datasets showed an increase in NTRK2 expression in
the proneural subtype of GBM, and a strong correlation between NTRK2 and EGFR
expression in glioma CpG island methylator phenotype (G-CIMP+) samples. We
showed that when TrkB and EGFR inhibitors were combined, the inhibitory effect on
A172 human GBM cells was more pronounced than when either inhibitor was given
alone. When U87MG GBM cells were xenografted into the flank of nude mice, tumor
growth was delayed by treatment with TrkB and EGFR inhibitors, given alone or
combined, only at specific time points. Intracranial GBM growth in mice was not
significantly affected by drug treatments.
Conclusions: Our findings indicate that correlations between NTRK2 and EGFR
expression occur in specific GBM subgroups. Also, our results using cultured cells
suggest for the first time the potential of combining TrkB and EGFR inhibition for the
treatment of GBM.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
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Response to reviews 
 
Manuscript number: #MOLE-D-20-00758 
Entitled: "Expression and pharmacological inhibition of TrkB and EGFR in 
glioblastoma” 
First author: Kelly V. Pinheiro 
Corresponding author: Rafael Roesler 
 
COMMENTS FROM EDITOR: 
 
We notice that the journal guidelines were not fully followed in the original version 
of the manuscript namely regarding the Abstract format and the number of figures 
(make use of supplementary figures as necessary). 
Response: We have now revised the Abstract and number of figures according 
to the journal guidelines. Figure 6 has become Supplementary Figure S1 in the 




1. Reviewer’s comment: The authors explore the hypothesis of a potential 
interaction between TrkB and EGFR in glioblastoma in which both tyrosine kinase 
Response to Reviewer Comments
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receptors have been implicated. Because TrkB and EGFR are known to 
functionally interact, the authors tested whether combining TrkB and EGFR 
inhibition, using respectively ANA12 and AG1478, may potentiate their respective 
effects when applied alone. Although the authors found no correlation between 
TrkB and EGFR expressions in glioblastoma using The Cancer Genome Atlas 
dataset, they found that co-inhibition of both receptors led to increased effects on 
the viability of cultured A172 cells (a model of human glioblastoma). However 
these findings could not be reproduced wit another cell line (U87MG cells). The 
authors performed a pharmacological interaction analysis using the Chou-Talalay 
method to find synergism between the two drugs in A172 cells, but antagonism 
in U87MG cells. To my opinion, these surprising results are very interesting and 
would have merited more attention/discussion. This point should be, at the very 
least, be addressed in the discussion section. 
Response: We thank the Reviewer for the thoughtful comment. Although the 
mechanisms underlying this opposite pattern of effects remain unclear and it is 
difficult to hypothesize about it at this point, we have included a new paragraph 
in the Discussion section to address this issue (page 18). As stated in the revised 
manuscript, one possibility involves different EGFR receptors expressed in the 
two cell lines: U87 MG cells only express wild-type EGFR, whereas A172 cells 
also express mutant TDM/18-26 EGFR.   
 
2. Reviewer’s comment: Finally, the authors tested pharmacological interaction 
between the two drugs using glioblastoma xenograft in mice. However, although 
both ANA12 and AG1478 seemed to slow down the progression of tumor growth, 
no further potentiation could be observed when both drugs were combined. In 
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addition, the previous beneficial effects of drugs alone that were observed during 
the course of the treatment were abolished at the end of the study. I have a major 
problem with this last part, which is most likely due to a poor experimental design 
rather than to a true biological effect. 
Response: We acknowledge the limitations in this experiment. We were 
interested in verifying whether pretreatment of the cells before inoculation would 
be a suitable model for GBM growth and studying drug effects. We still think the 
data is worth of inclusion in the paper despite the less clear effects.  
 
3. Reviewer’s comment: As stated above, the differential effects observed 
between A172 and U87 cell lines is rather surprising and would merit some 
discussion. For instance, how do the authors explain the apparent switch in IC50 
between both cell types for AG1478? Is it significant? For better clarity, mean +/- 
SEM should be provided in the Table of Figure 3. Also, very intriguing to me is 
the switch from synergism to antagonism between the two drugs when they are 
combined in A172 or in U87 cells. Can the authors provide an explanation? 
Response: As stated above, it is now unclear why we found contrasting effects 
between the two cell lines. However, further review of the literature showed us 
that U87 MG cells only express wild-type EGFR, whereas A172 cells also express 
mutant TDM/18-26 EGFR. We have included a new paragraph in the Discussion 
section to address this information, along with relevant new references (page 18). 
In addition, current literature recognizes that BDNF can play opposite actions 
depending on the cellular context. These differential effects may have to do with 
distinct isoforms of TrkB expressed in different tumors (Radin and Patel, 2017, 
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“BDNF: an oncogene or tumor suppressor?”, Anticancer Research 37: 3983-
3990). The same dependency on cellular environment might be related to the 
switch to antagonism in the presence of the EGFR inhibitor. This issue is now 
discussed in the revised manuscript (page 18). 
 
4. Reviewer’s comment: I also have difficulties to understand how the authors 
calculated separate IC50s for ANA12 and AG1478 in Figure 3, when both drugs 
are combined? The apparent IC50 is for both drugs combined, it is not possible 
to distinguish one from the other. Can the authors explain this point? 
Response: When IC50s are calculated using Graph Prisma, data can be plotted 
for each drug separately but IC50s are still calculated for the combined treatment 
when that is the case. Figure 3 has been revised for clarification. 
 
5. Reviewer’s comment: I have a real problem with the in vivo study. How were 
ANA12 and AG1478 doses and treatment regimen determined for the in vivo 
experiments? Do these doses correspond to their respective IC50s once they 
reach the xenograft? It is also very unlikely that the same dose reaches the 
intracranial tumor after crossing the BBB. Why did the authors use the same 
treatement for both types of xenograft? Also, does the treatement procedure lead 
to a stable presence of the drug overtime? In the discussion, the authors explain 
that these doses were determined based on previous studies but I failed to find 
any details in cited references. This point is critical for a good interpretation of the 
results since the drugs did not show satisfying effects in vivo, most likely because 
of inappropriate treatment procedure. In addition, because the number of animals 
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is extremely low (n=8 in Fig.5, n=5 in Fig.6), it is highly likely that the lack of 
apparent effect is due to the design of the study rather than to a biological effect. 
For all these reasons, I would suggest the authors to either remove the in vivo 
study or to provide more data and controls, including more mice per group and 
an analysis of drug efficiency at key time points (using Western Blots of pTrkB 
and pEGFR for ex). 
Response:  Drug doses were chosen on the basis of previous studies using in 
vivo injections of ANA-12 and AG1478 in rats and mice. Both drugs readily enter 
the rodent brain when given systemically. This information along with appropriate 
references have now been clarified in the revised manuscript (pages 8 and 9, 
references 20-25). We have not used the same doses for both in vivo models – 
in the first in vivo experiment, the cells were pre-treated before inoculation. We 
agree that the in vivo results offer limited conclusions, and at the present time our 
laboratory is shut down due to the lockdown and we are not able to perform 
further experiments to increase the sample size or provide additional measures. 
We have thus followed the Reviewer’s suggestion and removed the final in vivo 
experiment from the main article, changing Figure 6 to a Supplemental Figure.   
 
6. Reviewer’s comment: The figures are of low quality, which makes the text on 
graphs difficult to read. 
Response: Figures have been improved in the revised manuscript.  
 
7. Reviewer’s comment: On page 14, line 19: shouldn't "reduction of S phase" 
be "increase of S phase" instead? 
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Response: Yes, we thank the Review for pointing it out. That statement has been 
corrected in the revised manuscript. 
 
8. Reviewer’s comment: For better clarity, I would suggest to group results by 
cell cycle phases instead of doses in Figure 4. 
Response: Figure 4 has been revised according to the Reviewer’s suggestion. 
 
9. Reviewer’s comment: In Figure 5, the schematic drawing shows a 96-w plate 
while the text in the Method section indicates cultures in flasks. Similarly, the 
scheme shows xenograft in left flank while the text indicates right flank. 
Response: Figure 5 has been modified in order to correct the informations 
regarding the use of flasks and xenografts in the right flank.  
 
10. Reviewer’s comment: In Figure 6, the initial number of mice is 5, but only 3 
to 4 points are reported in the graphs. The authors should explain why individuals 
have been removed from the analysis. 
Response: Figure 6 has been removed from the main article and is now 
presented as Supplementary Figure S1. In this figure we summarize the results 
from an early experiment using the low sample number of 4-5 mice per group 
mentioned. Subsets of these mice were used for imaging the whole brain and 
perform images from brains sections to improve the fluorescence detection as 
previously described (Theranostics 2018; 8(14):3991-4002. 
doi:10.7150/thno.23709). Unfortunately, we were not able to euthanize all 
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animals on the same day in order to get data from all mice simultaneously. 
Moreover, mice that did not develop U87 tumors were removed from the study, 
resulting in a low sample size. Due to all these limitations, data shown in 
Supplementary Figure S1 should be taken as preliminary and illustrative. 
However, we still think it should made available as a supplementary figure to 




1. Reviewer’s comment: The logic for focusing, for instance, on the A172 cell 
line as a model is not quite acceptable. First, the authors postulate that Trkb and 
EGFR correlation is higher in LGG proneural GBM samples. No clear reasoning 
and mention of cell lines choices are given throughout the text. Furthermore, 
pieces of evidence in GBM literature of protein expression that define belonging 
of these cell lines to mesenchymal type, as well as the activity of several growth 
factor genes and extracellular matrix genes, were evaluated. Glioma cell lines, 
such as A172, vary in morphology and surface markers expression. High level of 
mesenchymal markers CD90 and CD105, fibroblast activation protein, and 
tenascin C was detected for the A172 cell line. Also, a high level of α2 smooth 
muscle actin gene. Data demonstrating high activity of genes encoding major 
angiogenesis inductors (VEGF, TGFβ1) and thrombospondin-1 in cell lines under 
study are in agreement with published data. Reduction of fetal serum content in 
culture medium from 10 to 5% increased the number of cells with CD73 and 
CD105 surface antigens in both cell lines. A172 and U87MG cell lines maintain 
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the main features of glioblastomas in early passages, and changes are definitely 
observed in late stages in culture. 
Besides, we have to raise awareness on the reliability of GBM models and 
the identity crisis of one-dimensional cell lines. So authors must address this 
issue. Therefore, In vitro data with proneural-like GBM cell lines should be 
considered after data obtained on TCGA. In vivo studies considering the best 
phenotype might show a much more significant robust response to the 
combination of the receptors inhibitors. The choices are critical to making that link 
with GBM data from patients. 
Response: The conclusion that TrkB and EGFR correlation is higher in LGG 
proneural GBM samples was obtained from gene expression data obtained from 
patient tumors from The Cancer Genome Atlas (TCGA n= 631 samples) GBM 
and TCGA Lower Grade Glioma and Glioblastoma (n= 702 samples) datasets, 
not from cell lines. The U87 cell line was chosen for in vivo experiments because 
of its tumorigenicity, and the A172 line has an overall similar biological profile 
when it comes to some important markers and mutations, according to the ATCC. 
However, it also expresses a mutant EGFR, which might partially explain the 
contrasting results we observed between the two cell lines in some assays (see 
page 18 in the revised manuscript). We acknowledge the limitations of cell lines 
as tumor models, but we think they were adequate for a first evaluation of the 
functional interactions between the receptor systems we studied. At this time it is 




2. Reviewer’s comment: No data available shows directly downstream signals 
(targets) blocked by the inhibitors. The authors must show the extension of these 
effects on those cell lines to be able to clarify the contradicting data on the 
synergism and antagonism, as well as the scarce effect in vivo. Western blottings 
and or other Protein assays for checking the activity of the main effectors of 
EGFR- and TrkB-stimulated pathways must be presented to further sustained the 
interpretation. Both cell cycle arrest and gene expression should be assessed in 
time and dose-response in vitro. 
Response: We agree that our study has limitations and one can always suggest 
additional experiments that would improve any given study. The focus of this very 
first study examining functional interactions between TrkB and EGFR was to 
verify whether the combined treatment could affect outcomes related to cell 
proliferation and tumor growth. We hope the Reviewers and Editors understand 
that, given the current situation with the COVID-19 pandemic    
 
3. Reviewer’s comment: The lack of use of glioma stem cell lines in vivo and 
neurospheres in this study in vitro turned out to be relevant. Since authors can 
perform in vivo experiments, very elegantly, PDX cells and iPS models would 
contribute significantly to the raised questions. There are GSC cell databanks 
already clearly presenting the differences among GBM subtypes as relevant for 
drug resistance and tumor progression. Nevertheless, at this point, it is 
reasonable to invest in more consistent data from either tumor samples obtained 
herein and, again, in vitro protein assays. Therefore, to unveil whether inhibitors 
protocol was sufficient or adequate to be extrapolated in vivo with the used cell 
lines. In the same way, discussion on the tumoral microenvironment playing a 
10 
 
more prominent role in the GBM tumor growth and susceptibility to 
pharmacological interventions are welcomed in this case. 
Response: We agree with the excellent suggestions for additional experiments 
made by the Reviewers. Certainly, including comparisons with iPS cells, for 
example, would be highly valuable. Unfortunately, at this time it is not possible to 
carry out such complex additional experiments in time for inclusion in this revised 
manuscript. We agree with the excellent comment regarding tumor 
microenvironment and we have included a brief discussion on this topic along 
with relevant references (pages 18 and 19). 
 
4. Reviewer’s comment: Overall, the quality of the statistical analysis is high. 
The data is generally solid and the manuscript is clear. Nevertheless, since 
correlation is main outcome in this work, authors should consider the use of FDR 
values; it is not clear whether it is only a terminology issue throughout the 
manuscript. 
Response: We thank the Reviewer’s comment acknowledging the quality of our 
statistical analysis. When analyzing gene expression, we chose the method using 
p values rather than FDR values, as an equally valid method. 
 
5. Reviewer’s comment: The conclusion made from the data in Figure 6 would 
be strengthened considerably by showing histopathology of the tumors. Many 
readouts from both simple H&E staining and IHC specific markers are essential 
to speculate beyond the pharmacological inhibition in vitro. For instance, 
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differences in Mitotic figures counting or Ki67 staining for the discussed cell cycle 
arresting would be more than incremental. 
Response: Unfortunately, it is not possible to recover the tumors and perform 
further analyses at this time. As explained above, we acknowledge the limitations 
of the experiment shown in Figure 6. This figure has been removed from the main 
article and is now a supplementary figure.      
 
Figure 1 Click here to access/download;Figure;Fig 1 MOLE-D-20-00758-R1.tif
Figure 2 Click here to access/download;Figure;Fig 2 MOLE-D-20-00758-R1.tif
Figure 3 Click here to access/download;Figure;Fig 3 MOLE-D-20-00758-R1.tif
Figure 4 Click here to access/download;Figure;Fig 4 MOLE-D-20-00758-R1.tif
Figure 5 Click here to access/download;Figure;Fig 5 MOLE-D-20-00758-R1.tif
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Background: A member of the Trk family of neurotrophin receptors, tropomyosin receptor kinase 
B (TrkB, encoded by the NTRK2 gene) is an increasingly important target in various cancer types, 
including glioblastoma (GBM). EGFR is among the most frequently altered oncogenes in GBM, 
and EGFR inhibition has been tested as an experimental therapy. Functional interactions between 
EGFR and TrkB have been demonstrated. In the present study, we investigated the role of TrkB 
and EGFR, and their interactions, in GBM.  
Methods and Results: Analyses of NTRK2 and EGFR gene expression from The Cancer Genome 
Atlas (TCGA) datasets showed an increase in NTRK2 expression in the proneural subtype of GBM, 
and a strong correlation between NTRK2 and EGFR expression in glioma CpG island methylator 
phenotype (G-CIMP+) samples. We showed that when TrkB and EGFR inhibitors were combined, 
the inhibitory effect on A172 human GBM cells was more pronounced than when either inhibitor 
was given alone. When U87MG GBM cells were xenografted into the flank of nude mice, tumor 
growth was delayed by treatment with TrkB and EGFR inhibitors, given alone or combined, only 
at specific time points. Intracranial GBM growth in mice was not significantly affected by drug 
treatments.  
Conclusions: Our findings indicate that correlations between NTRK2 and EGFR expression occur 
in specific GBM subgroups. Also, our results using cultured cells suggest for the first time the 
potential of combining TrkB and EGFR inhibition for the treatment of GBM. 
  
Keywords Brain tumor ● Epidermal growth factor receptor ● Glioblastoma ● Growth factor 






Growth factor receptors constitute many current and potential targets for molecularly specific 
therapies in cancer. The epidermal growth factor receptor (EGFR), a member of the ERBB family 
of transmembrane receptor tyrosine kinase (RTK) family, frequently shows gene amplification and 
activating mutations that contribute to driving the growth of lung and colorectal cancers [1]. EGFR 
is the target of clinically used small molecule inhibitors including erlotinib and gefitinib and 
monoclonal antibodies including cetuximab and panitumumab [2]. 
 EGFR is among the most frequently altered oncogenes in glioblastoma (GBM), with 57% 
of tumors analyzed by the The Cancer Genome Atlas Research Network (TCGA) showing 
amplification, mutation, rearrangement, or altered splicing [3]. GBM is the most aggressive type 
of primary malignant brain tumor. Current treatment based on combining surgical resection 
followed by radiotherapy and chemotherapy results in a median overall survival of less than 2 
years [4, 5]. To date, clinical trials with EGFR inhibitors in patients with GBM have failed to 
successfully improve outcomes [6, 7]. A proposed experimental strategy to reduce resistance and 
improve effectiveness has been to combine EGFR inhibitors with other targeted agents acting on 
pathways that crosstalk with EGFR signaling [8, 9]. 
 EGFR has been shown to functionally interact with tropomyosin receptor kinase B (TrkB, 
encoded by the NTRK2 gene), a member of the Trk family of neurotrophin receptors. 
Neurotrophins are secreted proteins importantly involved in central nervous system development, 
neurogenesis, and neuronal survival and plasticity [10]. Increasing evidence indicates that cancers 
can hijack neurotrophin signaling systems to promote tumor progression and resistance to 
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treatment [9, 11]. In colorectal cancer cells, TrkB activation by its endogenous ligand, brain-
derived neurotrophic factor (BDNF), promotes resistance against the EGFR inhibitor cetuximab, 
whereas co-treatment with TrkB and EGFR inhibitors reduce cell viability [12]. 
 GBM tumors express BDNF and TrkB, and TrkB activation enhances the viability of brain 
tumor stem cells (BTSCs) from human GBMs, whereas its inhibition reduces BTSC growth [13]. 
TrkB blockade also hinders viability of cultured human GBM cells [14]. BDNF secreted by more 
differentiated GBM cells supports the growth of TrkB-expressing GBM BTSCs [15]. NTRK gene 
fusions are currently established as oncogenic drivers of various adult and pediatric tumor types, 
and larotrectinib, a first-in-class small molecule Trk inhibitor, has received approval for patients 
with solid tumors harboring NTRK fusions [16, 17]. A gene fusion involving NTRK2 has been 
found to confer distinctive morphology and an aggressive phenotype in a case of low-grade glioma 
[18]. 
 Here, we investigated the role of TrkB and EGFR in GBM. First, we show data on the 
expression of NTRK2 and correlations with EGFR expression in GBM tumors from The Cancer 
Genome Atlas (TGCA) datasets. We then went on to examine the effects of inhibiting EGFR and 
TrkB receptors, either alone or in combination, in experimental models of GBM.  
 
Materials and methods 
 




NTRK2 expression levels were examined in previously described The Cancer Genome Atlas 
(TCGA n= 631 samples) GBM dataset and TCGA Lower Grade Glioma and Glioblastoma (n= 
702 samples) dataset. We used the data from gene expression array (platform: AffyU133a, version: 
2017-09-08), gene expression RNAseq (platform: IlluminaHiSeq, version: 2017-09-08) and copy 
number (type: gene-level GISTIC2 threshold, version: 2017-09-08), data were obtained from the 
University of California–Santa Cruz Xena Public Data Hubs website at http://xena.ucsc.edu/. We 
analyzed the expression levels of NTRK2 regarding primary disease, primary tumor and recurrent 
samples, cytosine-phosphate-guanine (CpG) island methylator phenotype (G-CIMP), TCGA 
molecular subtypes, and the correlation with EGFR expression and amplification. Additionality, 
we evaluated the correlation between gene expression levels of NTRK2 with patient survival 
outcomes. 
 
Cell culture  
 
Human GBM cells A172 and U87MG were obtained from American Type Culture Collection 
(Rockville, MD, USA)  and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) low 
glucose  supplemented with 10% fetal bovine serum (FBS, Gibco® by Thermo Fisher Scientific, 
Life Technologies, Brazil), 1% penicillin/streptomycin and 0.1% fungizone® (250 mg/kg; 
Invitrogen Life Technologies, São Paulo, Brazil). Cells were maintained in a humidified 






Drug treatments  
 
Selective antagonists of TrkB (ANA-12) and EGFR (Tyrphostin AG 1478) were obtained from 
Sigma Aldrich (St. Louis, MO). ANA-12 was diluted in dimethyl sulfoxide (DMSO) in a stock 
solution of 6140 µM and AG 1478 was diluted in ethanol (EtOH) in a stock solution of 3167 µM. 




After confluence, A172 and U87MG cells were trypsinized, placed in 96‐ well plates at an initial 
density of 5.0 × 103 cells per well and after 24h the medium was replaced by increasing 
concentrations of ANA-12 (0, 1, 10, 20, 30 and 50 µM), AG- 1478 (0, 1, 5, 10, 20 and 30 µM) and 
also combinations of both inhibitors for 24, 48 or 72 h , while the control cells were maintained in 
DMSO or  EtOH when the treatments were used alone or a vehicle solution (DMSO plus EtOH) 
when the treatments were used in combination. In any of the situations the vehicles used did not 
exceed the concentration of 1% (v/v). The effect on cell cytotoxicity was evaluated using the trypan 
blue exclusion method in the Neubauer chamber [12, 19]. All assays were performed in triplicate 




To assess cell cycle, GBM cells were cultured in 12-well plates under the same conditions as 
described above and after 24 h of exposure to treatments cells were detached, centrifuged and 
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washed with PBS twice. The cells were then resuspended in 50 μg/ml propidium iodide (Sigma-
Aldrich, St. Louis, Mo., USA) in 0.1% Triton X-100 in 0.1% sodium citrate solution and incubated 
on ice and protected from light for 15 min. The cells were analyzed by flow cytometry (Attune® 





Experimental procedures for  the subcutaneous xenograft GBM model were performed in 
accordance with the Brazilian Guidelines for the Care and Use of Animals in Research and 
Teaching [DBCA, published by National Council for the Control of Animal Experimentation 
(CONCEA), and approved by the institutional Animal Care Committee (Comissão de Ética no 
Uso de Animais CEUA, Hospital de Clínicas de Porto Alegre-HCPA), under protocol number 
20160098. Animal experiments for the orthotopic xenograft GBM model were carried out under 
Animals (Scientific Procedures) Act, 1986 and in accordance to institutional guidelines. 
 
Animals and tumor xenografts 
 
Balb/c nude mice (6 to 12 weeks old) were obtained from the University Hospital Animal Research 
Facility (UEA, CPE-HCPA) or from Charles River Laboratories. Animals were housed four per 
cage and kept under aseptic conditions in ventilated cages, maintained on a 12 h light/dark cycle 
at a room temperature of 22 ± 2°C. They were allowed ad libitum access to standardized pellet 
food and water. For the ex-vivo pharmacological inhibition, U87MG cells were cultured in 75 cm2 
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or 175 cm2 culture flasks and treated with 13.85 µM of ANA-12, 13.26 µM of AG 1478 (alone or 
in combination) or vehicle (DMSO plus EtOH) for 24 h. A total of 1 × 106 viable cells were 
processed in serum-free DMEM and diluted 1:1 with Matrigel (Corning, Corning, USA) and then 
injected subcutaneously (s.c) into the right flank of nude mice (6-8 mice per group). Measurements 
started five days after cells inoculation, when tumors reached approximately 40-75 mm3. The 
dimensions, length (L) and width (W), of the resulting tumors were determined every two days 
using a manual caliper, and the tumor volume (mm3) was calculated using the formula:  tumor 
volume = [length2 x width/2]. When tumors reached the endpoint (800-1000 mm3) mice were 
euthanized, and the tumors were excised, measured, and weighed. 
 For the orthotopic xenograft model, mice were anesthetized with isoflurane (4% oxygen) and 
placed in a stereotactic platform. The tops of the heads were disinfected, and a small incision was 
made in the scalp over the midline. A burr hole was made in the skull to a position 2 mm posterior 
and 1.5 mm lateral to the bregma in the right cerebral hemisphere. Next, mice were injected with 
40,000 U87MG cells processed in serum-free DMEM in a volume of 2 µl using an injector syringe 
pump. The burr hole in the skull was closed with sterile bone wax and veterinary tissue glue was 
used to seal the incision. After surgery, the mice were placed in a recovery cage set to 37 °C until 
the animal recovered consciousness. Mice were monitored daily for signs of sickness, pain or 
weight loss. Seven days followed the surgery the animals were randomized into 4 groups (n=5 per 
group) to receive intraperitoneal (i.p.) injections for 21 days, and were treated by a blinded 
investigator with ANA-12 (1 mg/kg/daily plus vehicle for AG1478 every 3 days), AG1478 (10 
mg/kg every three days plus vehicle for ANA-12 daily), ANA-12 (1 mg/kg daily) plus AG 1478 
(10 mg/kg every three days). Control animals received ANA-12 and vehicle (DMSO 2% in saline 
solution 0.9%) daily and vehicle for AG1478 (DMSO 30µl every three days).  Drug doses for in 
9 
 
vivo experiments were chosen on the basis of previous studies [20 – 24]. Both drugs readily enter 




Administration of 5-aminolevulinic acid (5-ALA), that leads to the synthesis and accumulation of 
fluorescent protoporphyrin IX (PPIX), has been used with fluorescence-guided surgery to directly 
visualize high-grade gliomas. After 21 days of treatment, the animals received an i.p. injection of 
5-ALA; 50 mg/kg and after 1 hour the mice were euthanized by cervical dislocation and the brains 
were removed to be analyzed. The IVIS system was used to record the ex-vivo fluorescent signal 
from tumors. First, we imaged the whole brains and next we used a brain matrix to cut sequential 
1 mm slices, in order to improve fluorescence detection, and the slices were also imaged.  Data 
acquisition and analysis was performed with Living Image software (Caliper LS living image 
version: 4.5.2.18424-september 11 2015, camera: IS1621N6980, Andor, iKon). In radiant 
efficiency mode, the wavelengths for emission and excitation were 620 and 420 respectively, and 
fixed size of regions of interest (ROIs) were drawn covering the whole tumor. The fluorescent 





Statistical analysis of gene expression in two or more groups from the TCGA transcriptome 
datasets were performed using Welch's t-test and Kruskal-Wallis test for significance and Dunn’s 
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tests for post hoc comparisons, respectively. Correlation analysis were performed by the Pearson 
correlation method. Survival distribution was estimated according to the Kaplan–Meier method 
using a median cut-off and log-rank statistics. These analyses were executed using the Graphpad 
8.0 software. Significant differences were revealed by p values below 0.05.  
 Experimental data were expressed as mean ± SEM. In vitro and in vivo experiments were 
analyzed using the GraphPad Prism software package, v. 5.0 (GraphPad, San Diego, CA). The 
level of significance between different experimental groups was performed using analysis of 
variance (ANOVA) followed by appropriate post-hoc tests; p < 0.05 was considered statistically 
significant. A drug combination analysis was performed based on the 50% inhibitory concentration 
(IC50) of the treatments. For calculation of IC50 data were fitted in a dose response curve 
(Graphpad Prism v. 5.0) using the equation Y=100/(1+10^((X-LogIC50))). The interaction 
between ANA-12 and AG-1478 was assessed by the combination index method (Cl) [26]. 
Synergism, addition and antagonism between drug combinations were defined as CI < 0.9, CI = 




NTRK2 expression levels are increased in lower grade glioma, proneural GBM 
subtype and GBM methylated phenotype in GBM patients 
 
We evaluated TCGA GBM datasets to explore whether NTRK2 expression correlates with EGFR 
expression, GBM subtype and patient survival. First, we classified TCGA samples by primary 
disease type between lower grade glioma (LGG) and GBM, based on array data available for 702 
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samples. NTRK2 expression was increased in LGG in comparison to GBM samples (Fig. 1A, p < 
0.0001). We also evaluated the levels of NTRK2 across normal brain samples, primary and 
recurrent tumors, however, no statistical differences were observed between these groups (Fig. 1B, 
p = 0.220). Based on the definition of GBM molecular subtypes, we found that NTRK2 expression 
was lower in the mesenchymal subtype when compared with neural and proneural subtypes (Fig. 
1C, p < 0.01). NTRK2 expression was highest in the proneural group in comparison with classical 
and mesenchymal subtypes (Fig. 1C, p < 0.0001). Given that the proneural group is associated 
with IDH mutations and IDH-mutant gliomas manifest the cytosine-phosphate-guanine (CpG) 
island methylator phenotype (G-CIMP), we evaluated the expression of NTRK2 regarding the 
methylation phenotype between G-CIMP+ and G-CIMP-. We observed an increased expression of 
NTRK2 in G-CIMP+ samples (Fig. 1D, p < 0.01), which is consistent with the increased expression 
in the proneural subtype. 
 
Correlations between NTRK2 and EGFR expression in GBM tumors 
 
To analyze whether the NTRK2 expression correlates with EGFR levels, we performed correlation 
analysis across samples registered with TCGA dataset. We detected a weak correlation between 
NTRK2 and EGFR expression when considering all GBM samples together (Fig. 1E, correlation 
= 0.1603, p = 0.0002) and G-CIMP GBM samples (Fig. 1G, correlation = 0.1869, p = 0.0001). A 
moderate correlation between NTRK2 and EGFR expression was found in G-CIMP+ samples (Fig. 
1F, correlation = 0.3443, p = 0.0221). 
 We also determined the relationship between NTRK2 expression and patient overall 
survival (Fig. 1H), using median of NTRK2 expression as a cutoff between low and high 
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expression. We further looked at the effect of NTRK2 expression in patients stratified by EGFR 
amplification (Fig. 1I). Survival of GBM patients was not significantly different when tumors with 
high and low NTRK2 expression levels were compared. 
 
 
Figure 1 should be inserted here 
 
 
Selective inhibition of TrkB and EGFR decreases GBM cell viability 
 
To examine the effects of TrkB and EGFR inhibition on cell viability, GBM cells were treated 
with ANA-12 and AG 1478 alone or in combination and viability was assessed by the trypan blue 
exclusion method. Time course analysis showed that both single treatments decreased A172 and 
U87MG cell viability when compared with control cells treated with vehicle (p < 0.001). The 
effect was observed in A172 cells after 48 hours of treatment with ANA-12 at 10 μM or AG1478 
at 30 μM (Fig. 2A, 2B). A similar effect was observed in U87MG cells after 24 hours of treatment 
with the dose of 10 μM of ANA-12 or AG1478 (Fig. 2C, 2D).  We also analyzed whether the 
reduction of cell viability with ANA-12 or AG1478 were dose-dependent. As depicted in Fig. 2, 
both treatments showed features of dose-dependent effect in A172 and U87MG cells. After time 
course and dose-response curves analysis, we defined proper doses and time to evaluate the effect 
of the combination (ANA-12 plus AG1478) on cell viability. When the two drugs were combined 
the inhibitory effect was more pronounced in A172 cells compared to either IC50-equivalent 
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isolated drugs and in the combination of both drugs in higher doses (see Fig. 2I for detailed results 
and p values for specific comparisons). In contrast, the effect of the combination treatment was 




Figure 2 should be inserted here 
 
 
Pharmacological interactions between TrkB and EGFR inhibitors 
 
In order to evaluate drug interaction effects, IC50-values were calculated from the effects seen in 
the cytotoxicity assay (Fig. 3). ANA-12 had IC50 values of 10.0 (7-14) μM and 13.85 (11-17) μM 
for A172 and U87MG cells, respectively. IC50 values of AG1478 were 20.0 (16-21) μM for A172 
cells and 13.26 (11-16) μM for U87MG cells (Fig. 3A). Pharmacological interactions of the 
combined treatment with ANA-12 and AG1478 were investigated using cytotoxicity as the chosen 
outcome and evaluated by Chou-Talalay method (Chou and Talalay 1984). Synergism, addition 
and antagonism for drug combinations was defined as CI < 0.9, CI = 0.9-1.1 and CI > 1.1, 
respectively.  We observed synergy in A172 cells (CI = 0.75). However, in U87MG cells the 








Figure 3 should be inserted here 
 
 
TrkB and EGFR inhibitors induce changes in cell cycle features of GBM cells 
 
Effects on cell cycle were evaluated by flow cytometry after treatment with ANA-12 and AG 1478 
alone or in combination in GBM cells. As shown in Fig. 4, the TrkB inhibitor induced a significant 
reduction in S phase, which starts at the dose of 10 μM and persists at a dose of 20 μM in A172 
cells (Fig. 4A p < 0.001 and p < 0.0001, respectively). An increase in cells in the S phase after 
TrkB inhibition was observed in U87MG cells at the dose of 50 μM (p < 0.05, Fig. 4D). Treatment 
with 30 μM of AG 1478 significantly increased the number of A172 and U87MG cells in G0/G1 
phase when compared with control cells (Fig. 4B, 4E, p < 0.01 and p < 0.05, respectively).  The 
combined treatment lead to a combination of effects leading to both accumulation of cells in G0/G1 
and reduction of S phase in A172 cells (Fig. 4C p < 0.05 and p < 0.01). The combined treatment 
did not cause significant changes in the cell cycle of U87MG cells; however, we could observe a 
small percentage of cells in Sub-G1 phase when compared with controls (Fig. 4F, p < 0.05). 
 
 





Long-term effects of TrkB and EGFR inhibition in a GBM xenograft mouse model 
 
To explore the roles of EGFR and TrkB during tumorigenesis, we used a preclinical subcutaneous 
xenograft GBM model. U87MG cells were treated with ANA-12, AG 1478, ANA-12 plus AG 
1478 and DMSO or EtOH. After 24 h, the animals were randomized and viable pre-treated U87MG 
cells were injected subcutaneously into the right flank of mice (Fig. 5A). Fig. 5B illustrates tumor 
volume size across different days. Tumor size was significantly different in day 15 in all treatment 
groups when compared with controls given vehicle. Mice that received cells treated with ANA-
12, alone or combined with AG 1478, also showed smaller tumors at day 31. The apparent 
reduction in tumor size in all drug-treated groups compared to controls at day 45 did not reach 
statistical significance (Fig. 5C). When tumors reached 800-100 mm3 the mice were euthanized, 
and the tumors were excised, and weight and volume were determined. Ex-vivo tumor analysis 
showed an apparent reduction in tumor volume when compared treatment groups with control, 
however, these differences did not reach statistical significance (Fig. 5D). Moreover, there were 
no statistically significant differences among groups regarding tumor weight (Fig. 5E). We also 
evaluated possible differences in survival comparing treatment groups with control group. 
Although the median survival days of the control group (38 days) was lower when compared to 
treatment groups (ANA-12, 45 days; AG 1478, 41 days; ANA-12+AG 1478, 44 days), no 









Figure 5 should be inserted here 
 
 
Lack of effect of combined TrkB and EGFR inhibition on intracranial GBM tumor 
growth 
 
We tested the hypothesis that the combined inhibition of TrkB plus EGFR would inhibit the growth 
of intracranial GBM in mice. Seven days after inoculation of U87MG cells, mice were randomized 
to receive i.p. injections in a period of 21 days with ANA-12 (1 mg/kg daily plus vehicle every 3 
days), AG1478 (10 mg/kg every three days plus vehicle daily), ANA-12 (1 mg/kg daily) plus AG 
1478 (10 mg/kg every three days) and vehicle daily. During the treatment period, mice were 
monitored daily for any signs of sickness, pain or weight loss. The tumor growth was analyzed by 
ex-vivo brain fluorescent imaging of the different groups using the IVIS system after 29 days after 
cell inoculation. Tumor fluorescence did not reveal a significant difference among groups (p = 




Gene expression analysis in GBM tumor datasets showed an increased NTRK2 expression in 
proneural, G-CIMP+ GBMs. Interestingly, significant correlations between NTRK2 and EGFR 
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expression levels were found in GBM, particularly in G-CIMP+ tumors. Previous analyses of 
TCGA GBMs have shown that G-CIMP+ glioblastomas presented reduced mRNA levels for 
EGFR due to epigenetic regulation [27]. The proneural G-CIMP phenotype confers a survival 
advantage for GBM patients [3], and its possible relationship with NTRK2 expression revealed 
here warrants further exploration. 
One of the main findings in the present study was that the combined inhibition of TrkB and 
EGFR was more pronounced than either treatment given alone in impairing A172 GBM cell 
viability. This result is consistent with the view that TrkB inhibition may sensitize cancer cells to 
the effects of EGFR inhibitors [28]. ANA-12, originally developed as an experimental 
antidepressant, selectively and efficiently inhibits TrkB by binding to both low- and high-affinity 
sites on the receptor extracellular domain [21]. AG 1478 is a selective EGFR inhibitor that shares 
a structural quinazoline main chain with the clinically used EGFR inhibitors gefitinib and erlotinib 
[20]. The results observed with these two small-molecule compounds in two different mouse GBM 
xenograft models were less clear. When cells were pretreated with drug treatments before being 
xenografted into the flanks of nude mice, treatments were able to slow tumor growth only at 
specific time points (15 and 31 days after cell inoculation), but drug-treated tumors were able to 
reach sizes comparable to controls by the end of the follow-up period. In addition, treatments did 
not significantly change tumor progression assessed by fluorescence in mice receiving GBM cells 
intracranially followed by systemic drug treatments. Given the potency of ANA-12 and AG1478 
inhibition of cell viability in vitro, we expected to observe pronounced drug effects in in vivo 
models. A possible limitation was measuring fluorescence only at the end of treatment rather than 
at different time points during treatment. Importantly, EGFR may have a dual role, contributing to 
tumor progression but also conferring increased DNA damage response and high sensitivity to the 
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inhibitor talazoparib [29]. Thus, differential roles of EGFR signaling could occur under the 
different experimental conditions we used (for example, regulation by the tumor 
microenvironment in in vivo assays), resulting in contrasting findings. The lack of effects may also 
be related to the choice of drug doses in our experiments. The drug doses and treatment regimens 
we used for in vivo experiments were based on previous studies that used xenograft models of 
GBM and other cancer types [22, 24, 25]. It is still possible that, as suggested by our results shown 
in Fig. 3, the two drugs used show antagonistic activity in U87MG cells. Another point worth 
mentioning is that, together, the results obtained in our in vitro and flank xenograft experiments 
might suggest that TrkB and EGFR inhibition can delay GBM growth in the short-term, but not 
after longer delays, when tumors are able to recover full growth. 
One issue worthy discussing is the opposite pattern of effects on cytotoxity between the 
two cell lines. Pharmacological interaction analysis showed synergism in A172 cells but 
antagonism in U87 MG cells. In terms of genetic profiles, both A172 and U87 MG cells are mutant 
for both CDKN2A and PTEN. However, U87 MG cells express only wild-type EGFR, whereas 
A172 cells also express TDM/18-26 mutant EGFR [30, 31]. This biological difference might be 
crucial to explain the contrasting effects we observed between cell lines. In addition, we have 
previously observed, in experiments using medulloblastoma cells, that BDNF/TrkB signaling may 
have opposite effects on cell viability, so TrkB activation can either induce or prevent cytotoxicity 
depending on drug combinations and experimental conditions [32 - 34]. In fact, BDNF can play 
opposite actions depending on changes in cellular context. These differential effects may involve 
distinct isoforms of TrkB expressed in different cell tumor types [34]. This dependency on cellular 
environment might also be related to the switch from synergism to antagonism we observed when 
TrkB inhibition was combined with EGFR inhibitor. GBM tumors interact in complex ways with 
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a microenvironment consisting of glial, endothelial, and immune cells. Several signaling 
molecules, including growth factors, mediate intercellular communication between GBM cells and 
cells composing the microenvironment [35 - 37]. It is thus possible that the interactions between 
receptors such as TrkB and EGFR in GBM, as well as the effects of receptor inhibitors, are 
modulated by biochemical signals from the microenvironment. It is also possible that inhibitors 
interact directly with receptors on cells in the microenvironment, resulting in changes of drug 
responses in vivo compared to in vitro models. These are complex issues that warrant further 
research in the field of targeted therapies for GBM.          
  GBM differentiated cells have been shown to secrete BDNF to stimulate TrkB in GBM 
stem cells and induce them to secrete nerve growth factor inducible (VGF), a neuropeptide that 
promotes survival and growth of GBM stem-like and differentiated cells [15]. TrkB knockdown 
or pharmacological inhibition of TrkB hinders BDNF-dependent GBM stem-like cell growth [13]. 
TrkB-containing exosomes promote the transfer of aggressiveness between GBM cells [38]. EGFR 
inhibition has been proposed as a therapeutic strategy in GBM and has been tested in preclinical 
[39 – 41] and clinical [42, 43] studies, with mixed results. One previous study examined the 
interaction between TrkB and EGFR in experimental GBM and showed that stimulation of 
neurotrophin signaling can overcome the inhibitory effects of EGFR inhibition on GBM cell 
growth [13]. The present study is the first one to verify whether the combined inhibition of TrkB 
and EGFR may effectively reduce GBM growth.      
In summary, analysis of TCGA tumors showed that correlations between NTRK2 and 
EGFR expression can be observed in GBM, and the role of TrkB and EGFR in the proneural, G-
CIMP+ subtype of GBM should be further investigated by future studies. In addition, our results 
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using cultured cells indicate for the first time the potential of combining TrkB and EGFR inhibition 
for the treatment of GBM, however we could not observe pronounced effects in vivo.     
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Legends for figures 
 
Fig 1 NTRK2 expression and its correlation with EGFR expression levels in TCGA GBM datasets. 
Transcript levels of NTRK2 were examined in previously described transcriptome datasets from 
the TCGA GBM dataset (n = 631 samples) and the TCGA Lower Grade Glioma (LGG) and GBM 
(n =702 samples) dataset. (A) Expression levels of NTRK2 in LGG and GBM patient cohorts. (B) 
Normal brain, primary and recurrent GBM samples. (C) GBM subtypes. (D) cytosine-phosphate-
guanine (CpG) island methylator phenotype (G-CIMP). Data was presented in violin plot format 
as log2-transformed signal intensity and statistical analyses were performed using Kruskal-Wallis 
test followed by Dunn’s post hoc tests, * p < 0.05; ** p < 0.01; *** p < 0.001 and **** p < 0.0001 
for significance. (E, F, G) Correlation between NTRK2 and EGFR expression levels in the TCGA 
GBM dataset. Pearson correlation coefficients and their p values were calculated using GraphPad 
prism. Trend lines were determined by the linear regression model. Overall survival probability in 
a set of 523 samples from the TCGA GBM cohort. (H) all samples and (I) EGFR amplified 
samples. Patients were grouped according to low or high expression of NTRK2. Survival 
distribution was estimated according to the Kaplan-Meier method using median cut-off selection 
and log-rank statistics. 
 
Fig 2 Inhibition of TrkB and EGFR alone or in combination reduces human GBM cell viability. 
Time course analysis of cell viability, by trypan blue cell counting, were performed after 24, 48 
and 72 h of exposure to ANA-12 or AG 1478 exposure in A172 (A, B) and U87MG (C, D) cells. 
Dose-response curves were evaluated by trypan blue cell counting after treatment with increasing 
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concentrations of ANA-12 (1-50 µM) or AG 1478 (1-30 µM) for 48 h in A172 cells (E, F) and 24 
h in U87MG cells (G, H). The drug vehicles (DMSO or EtOH) served as controls. Dose-response 
curves after combined treatment with ANA-12 and AG 1478 were evaluated after 48 h of drug 
exposure in A172 cells (I) and 24 h in U87MG cells (J). Data are expressed by mean ± SEM and 
represent three independent experiments *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
compared to control cells; # p < 0.05 and ### p < 0.001 compared to ANA-12; ++ p < 0.01 and 
+++ p < 0.001 compared with AG 1478; one-way ANOVA followed by Tukey tests for multiple 
comparisons). 
 
Fig 3 Synergistic effect after combined inhibition of TrkB and EGFR in A172 GBM cells. A172 
and U87MG cell lines were treated with varying concentrations of ANA-12 and AG 1478 alone 
or in combination. The IC50-values were calculated from the dose-response curves after different 
exposure times (48 h for A172 and 24 h for U87MG cells) and expressed with their respective 
95% confidence intervals and summarized in the table (A). The combination index (CI) was 
determined by the method of Chou-Talalay [20] and data are presented as mean ± SEM (B). 
 
Fig 4 Effects of EGRF and TrkB inhibition on GBM cell cycle. Cells were exposed to ANA-12, 
AG 1478 or ANA-12 plus AG 1478 for 24 h, and the percentages of cells in G0/G1, S and G2/M 
phases of the cell cycle were evaluated. Two wells were assigned to each treatment and the 
experiments were repeated at least three times. Data are presented as mean ± SEM of the 
percentage of cells in each phase. * p < 0.05; ** p < 0.01; *** p < 0.001 and **** p < 0.0001 




Fig 5 Inhibition of TrkB and EGFR alone or in combination in a subcutaneous GBM xenograft 
mouse model. U87MG cells were pretreated in vitro for 24 h with ANA-12 (13.85 μM), AG-1478 
(13.26 μM) or ANA-12 plus AG-1478, and the viable cells were injected into the flanks of nude 
mice (6-7 mice per group) as shown in the schematic drawing (A).  Caliper measurements were 
used to determine the displayed subcutaneous tumor volume. Mice were euthanized and tumors 
were excised when volume reached approximately 800-1,000 mm3 (B) Tumors were measured 
every 2 days and volumes were calculated as described in materials and methods section. Tumor 
growth is represented by tumor volume (mm3) at the indicated days; Control (n= 7), ANA-12 (n= 
8), AG 1478 (n= 8) and ANA-12 plus AG 1478 (n= 8) (C) Tumor growth curve is shown on 
selected time points of 15, 31 and 45 days to highlight statistical differences (D). Tumor volumes 
(mm3) at the time of tissue harvest. (E) Tumor weight (mg) at the time of tissue harvest are shown 
in (F) Kaplan-Meier curves presenting percent of mice surviving following tumor implantation. 
Data are expressed as mean ± SEM (* p < 0.05; ** p < 0.01). Statistical analysis was performed 
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Background: A member of the Trk family of neurotrophin receptors, tropomyosin receptor kinase 
B (TrkB, encoded by the NTRK2 gene) is an increasingly important target in various cancer types, 
including glioblastoma (GBM). EGFR is among the most frequently altered oncogenes in GBM, 
and EGFR inhibition has been tested as an experimental therapy. Functional interactions between 
EGFR and TrkB have been demonstrated. In the present study, we investigated the role of TrkB 
and EGFR, and their interactions, in GBM.  
Methods and Results: Analyses of NTRK2 and EGFR gene expression from The Cancer Genome 
Atlas (TCGA) datasets showed an increase in NTRK2 expression in the proneural subtype of GBM, 
and a strong correlation between NTRK2 and EGFR expression in glioma CpG island methylator 
phenotype (G-CIMP+) samples. We showed that when TrkB and EGFR inhibitors were combined, 
the inhibitory effect on A172 human GBM cells was more pronounced than when either inhibitor 
was given alone. When U87MG GBM cells were xenografted into the flank of nude mice, tumor 
growth was delayed by treatment with TrkB and EGFR inhibitors, given alone or combined, only 
at specific time points. Intracranial GBM growth in mice was not significantly affected by drug 
treatments.  
Conclusions: Our findings indicate that correlations between NTRK2 and EGFR expression occur 
in specific GBM subgroups. Also, our results using cultured cells suggest for the first time the 
potential of combining TrkB and EGFR inhibition for the treatment of GBM. 
  
Keywords Brain tumor ● Epidermal growth factor receptor ● Glioblastoma ● Growth factor 






Growth factor receptors constitute many current and potential targets for molecularly specific 
therapies in cancer. The epidermal growth factor receptor (EGFR), a member of the ERBB family 
of transmembrane receptor tyrosine kinase (RTK) family, frequently shows gene amplification and 
activating mutations that contribute to driving the growth of lung and colorectal cancers [1]. EGFR 
is the target of clinically used small molecule inhibitors including erlotinib and gefitinib and 
monoclonal antibodies including cetuximab and panitumumab [2]. 
 EGFR is among the most frequently altered oncogenes in glioblastoma (GBM), with 57% 
of tumors analyzed by the The Cancer Genome Atlas Research Network (TCGA) showing 
amplification, mutation, rearrangement, or altered splicing [3]. GBM is the most aggressive type 
of primary malignant brain tumor. Current treatment based on combining surgical resection 
followed by radiotherapy and chemotherapy results in a median overall survival of less than 2 
years [4, 5]. To date, clinical trials with EGFR inhibitors in patients with GBM have failed to 
successfully improve outcomes [6, 7]. A proposed experimental strategy to reduce resistance and 
improve effectiveness has been to combine EGFR inhibitors with other targeted agents acting on 
pathways that crosstalk with EGFR signaling [8, 9]. 
 EGFR has been shown to functionally interact with tropomyosin receptor kinase B (TrkB, 
encoded by the NTRK2 gene), a member of the Trk family of neurotrophin receptors. 
Neurotrophins are secreted proteins importantly involved in central nervous system development, 
neurogenesis, and neuronal survival and plasticity [10]. Increasing evidence indicates that cancers 
can hijack neurotrophin signaling systems to promote tumor progression and resistance to 
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treatment [9, 11]. In colorectal cancer cells, TrkB activation by its endogenous ligand, brain-
derived neurotrophic factor (BDNF), promotes resistance against the EGFR inhibitor cetuximab, 
whereas co-treatment with TrkB and EGFR inhibitors reduce cell viability [12]. 
 GBM tumors express BDNF and TrkB, and TrkB activation enhances the viability of brain 
tumor stem cells (BTSCs) from human GBMs, whereas its inhibition reduces BTSC growth [13]. 
TrkB blockade also hinders viability of cultured human GBM cells [14]. BDNF secreted by more 
differentiated GBM cells supports the growth of TrkB-expressing GBM BTSCs [15]. NTRK gene 
fusions are currently established as oncogenic drivers of various adult and pediatric tumor types, 
and larotrectinib, a first-in-class small molecule Trk inhibitor, has received approval for patients 
with solid tumors harboring NTRK fusions [16, 17]. A gene fusion involving NTRK2 has been 
found to confer distinctive morphology and an aggressive phenotype in a case of low-grade glioma 
[18]. 
 Here, we investigated the role of TrkB and EGFR in GBM. First, we show data on the 
expression of NTRK2 and correlations with EGFR expression in GBM tumors from The Cancer 
Genome Atlas (TGCA) datasets. We then went on to examine the effects of inhibiting EGFR and 
TrkB receptors, either alone or in combination, in experimental models of GBM.  
 
Materials and methods 
 




NTRK2 expression levels were examined in previously described The Cancer Genome Atlas 
(TCGA n= 631 samples) GBM dataset and TCGA Lower Grade Glioma and Glioblastoma (n= 
702 samples) dataset. We used the data from gene expression array (platform: AffyU133a, version: 
2017-09-08), gene expression RNAseq (platform: IlluminaHiSeq, version: 2017-09-08) and copy 
number (type: gene-level GISTIC2 threshold, version: 2017-09-08), data were obtained from the 
University of California–Santa Cruz Xena Public Data Hubs website at http://xena.ucsc.edu/. We 
analyzed the expression levels of NTRK2 regarding primary disease, primary tumor and recurrent 
samples, cytosine-phosphate-guanine (CpG) island methylator phenotype (G-CIMP), TCGA 
molecular subtypes, and the correlation with EGFR expression and amplification. Additionality, 
we evaluated the correlation between gene expression levels of NTRK2 with patient survival 
outcomes. 
 
Cell culture  
 
Human GBM cells A172 and U87MG were obtained from American Type Culture Collection 
(Rockville, MD, USA)  and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) low 
glucose  supplemented with 10% fetal bovine serum (FBS, Gibco® by Thermo Fisher Scientific, 
Life Technologies, Brazil), 1% penicillin/streptomycin and 0.1% fungizone® (250 mg/kg; 
Invitrogen Life Technologies, São Paulo, Brazil). Cells were maintained in a humidified 






Drug treatments  
 
Selective antagonists of TrkB (ANA-12) and EGFR (Tyrphostin AG 1478) were obtained from 
Sigma Aldrich (St. Louis, MO). ANA-12 was diluted in dimethyl sulfoxide (DMSO) in a stock 
solution of 6140 µM and AG 1478 was diluted in ethanol (EtOH) in a stock solution of 3167 µM. 




After confluence, A172 and U87MG cells were trypsinized, placed in 96‐ well plates at an initial 
density of 5.0 × 103 cells per well and after 24h the medium was replaced by increasing 
concentrations of ANA-12 (0, 1, 10, 20, 30 and 50 µM), AG- 1478 (0, 1, 5, 10, 20 and 30 µM) and 
also combinations of both inhibitors for 24, 48 or 72 h , while the control cells were maintained in 
DMSO or  EtOH when the treatments were used alone or a vehicle solution (DMSO plus EtOH) 
when the treatments were used in combination. In any of the situations the vehicles used did not 
exceed the concentration of 1% (v/v). The effect on cell cytotoxicity was evaluated using the trypan 
blue exclusion method in the Neubauer chamber [12, 19]. All assays were performed in triplicate 




To assess cell cycle, GBM cells were cultured in 12-well plates under the same conditions as 
described above and after 24 h of exposure to treatments cells were detached, centrifuged and 
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washed with PBS twice. The cells were then resuspended in 50 μg/ml propidium iodide (Sigma-
Aldrich, St. Louis, Mo., USA) in 0.1% Triton X-100 in 0.1% sodium citrate solution and incubated 
on ice and protected from light for 15 min. The cells were analyzed by flow cytometry (Attune® 





Experimental procedures for  the subcutaneous xenograft GBM model were performed in 
accordance with the Brazilian Guidelines for the Care and Use of Animals in Research and 
Teaching [DBCA, published by National Council for the Control of Animal Experimentation 
(CONCEA), and approved by the institutional Animal Care Committee (Comissão de Ética no 
Uso de Animais CEUA, Hospital de Clínicas de Porto Alegre-HCPA), under protocol number 
20160098. Animal experiments for the orthotopic xenograft GBM model were carried out under 
Animals (Scientific Procedures) Act, 1986 and in accordance to institutional guidelines. 
 
Animals and tumor xenografts 
 
Balb/c nude mice (6 to 12 weeks old) were obtained from the University Hospital Animal Research 
Facility (UEA, CPE-HCPA) or from Charles River Laboratories. Animals were housed four per 
cage and kept under aseptic conditions in ventilated cages, maintained on a 12 h light/dark cycle 
at a room temperature of 22 ± 2°C. They were allowed ad libitum access to standardized pellet 
food and water. For the ex-vivo pharmacological inhibition, U87MG cells were cultured in 75 cm2 
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or 175 cm2 culture flasks and treated with 13.85 µM of ANA-12, 13.26 µM of AG 1478 (alone or 
in combination) or vehicle (DMSO plus EtOH) for 24 h. A total of 1 × 106 viable cells were 
processed in serum-free DMEM and diluted 1:1 with Matrigel (Corning, Corning, USA) and then 
injected subcutaneously (s.c) into the right flank of nude mice (6-8 mice per group). Measurements 
started five days after cells inoculation, when tumors reached approximately 40-75 mm3. The 
dimensions, length (L) and width (W), of the resulting tumors were determined every two days 
using a manual caliper, and the tumor volume (mm3) was calculated using the formula:  tumor 
volume = [length2 x width/2]. When tumors reached the endpoint (800-1000 mm3) mice were 
euthanized, and the tumors were excised, measured, and weighed. 
 For the orthotopic xenograft model, mice were anesthetized with isoflurane (4% oxygen) and 
placed in a stereotactic platform. The tops of the heads were disinfected, and a small incision was 
made in the scalp over the midline. A burr hole was made in the skull to a position 2 mm posterior 
and 1.5 mm lateral to the bregma in the right cerebral hemisphere. Next, mice were injected with 
40,000 U87MG cells processed in serum-free DMEM in a volume of 2 µl using an injector syringe 
pump. The burr hole in the skull was closed with sterile bone wax and veterinary tissue glue was 
used to seal the incision. After surgery, the mice were placed in a recovery cage set to 37 °C until 
the animal recovered consciousness. Mice were monitored daily for signs of sickness, pain or 
weight loss. Seven days followed the surgery the animals were randomized into 4 groups (n=5 per 
group) to receive intraperitoneal (i.p.) injections for 21 days, and were treated by a blinded 
investigator with ANA-12 (1 mg/kg/daily plus vehicle for AG1478 every 3 days), AG1478 (10 
mg/kg every three days plus vehicle for ANA-12 daily), ANA-12 (1 mg/kg daily) plus AG 1478 
(10 mg/kg every three days). Control animals received ANA-12 and vehicle (DMSO 2% in saline 
solution 0.9%) daily and vehicle for AG1478 (DMSO 30µl every three days).  Drug doses for in 
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vivo experiments were chosen on the basis of previous studies [20 – 24]. Both drugs readily enter 




Administration of 5-aminolevulinic acid (5-ALA), that leads to the synthesis and accumulation of 
fluorescent protoporphyrin IX (PPIX), has been used with fluorescence-guided surgery to directly 
visualize high-grade gliomas. After 21 days of treatment, the animals received an i.p. injection of 
5-ALA; 50 mg/kg and after 1 hour the mice were euthanized by cervical dislocation and the brains 
were removed to be analyzed. The IVIS system was used to record the ex-vivo fluorescent signal 
from tumors. First, we imaged the whole brains and next we used a brain matrix to cut sequential 
1 mm slices, in order to improve fluorescence detection, and the slices were also imaged.  Data 
acquisition and analysis was performed with Living Image software (Caliper LS living image 
version: 4.5.2.18424-september 11 2015, camera: IS1621N6980, Andor, iKon). In radiant 
efficiency mode, the wavelengths for emission and excitation were 620 and 420 respectively, and 
fixed size of regions of interest (ROIs) were drawn covering the whole tumor. The fluorescent 





Statistical analysis of gene expression in two or more groups from the TCGA transcriptome 
datasets were performed using Welch's t-test and Kruskal-Wallis test for significance and Dunn’s 
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tests for post hoc comparisons, respectively. Correlation analysis were performed by the Pearson 
correlation method. Survival distribution was estimated according to the Kaplan–Meier method 
using a median cut-off and log-rank statistics. These analyses were executed using the Graphpad 
8.0 software. Significant differences were revealed by p values below 0.05.  
 Experimental data were expressed as mean ± SEM. In vitro and in vivo experiments were 
analyzed using the GraphPad Prism software package, v. 5.0 (GraphPad, San Diego, CA). The 
level of significance between different experimental groups was performed using analysis of 
variance (ANOVA) followed by appropriate post-hoc tests; p < 0.05 was considered statistically 
significant. A drug combination analysis was performed based on the 50% inhibitory concentration 
(IC50) of the treatments. For calculation of IC50 data were fitted in a dose response curve 
(Graphpad Prism v. 5.0) using the equation Y=100/(1+10^((X-LogIC50))). The interaction 
between ANA-12 and AG-1478 was assessed by the combination index method (Cl) [26]. 
Synergism, addition and antagonism between drug combinations were defined as CI < 0.9, CI = 




NTRK2 expression levels are increased in lower grade glioma, proneural GBM 
subtype and GBM methylated phenotype in GBM patients 
 
We evaluated TCGA GBM datasets to explore whether NTRK2 expression correlates with EGFR 
expression, GBM subtype and patient survival. First, we classified TCGA samples by primary 
disease type between lower grade glioma (LGG) and GBM, based on array data available for 702 
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samples. NTRK2 expression was increased in LGG in comparison to GBM samples (Fig. 1A, p < 
0.0001). We also evaluated the levels of NTRK2 across normal brain samples, primary and 
recurrent tumors, however, no statistical differences were observed between these groups (Fig. 1B, 
p = 0.220). Based on the definition of GBM molecular subtypes, we found that NTRK2 expression 
was lower in the mesenchymal subtype when compared with neural and proneural subtypes (Fig. 
1C, p < 0.01). NTRK2 expression was highest in the proneural group in comparison with classical 
and mesenchymal subtypes (Fig. 1C, p < 0.0001). Given that the proneural group is associated 
with IDH mutations and IDH-mutant gliomas manifest the cytosine-phosphate-guanine (CpG) 
island methylator phenotype (G-CIMP), we evaluated the expression of NTRK2 regarding the 
methylation phenotype between G-CIMP+ and G-CIMP-. We observed an increased expression of 
NTRK2 in G-CIMP+ samples (Fig. 1D, p < 0.01), which is consistent with the increased expression 
in the proneural subtype. 
 
Correlations between NTRK2 and EGFR expression in GBM tumors 
 
To analyze whether the NTRK2 expression correlates with EGFR levels, we performed correlation 
analysis across samples registered with TCGA dataset. We detected a weak correlation between 
NTRK2 and EGFR expression when considering all GBM samples together (Fig. 1E, correlation 
= 0.1603, p = 0.0002) and G-CIMP GBM samples (Fig. 1G, correlation = 0.1869, p = 0.0001). A 
moderate correlation between NTRK2 and EGFR expression was found in G-CIMP+ samples (Fig. 
1F, correlation = 0.3443, p = 0.0221). 
 We also determined the relationship between NTRK2 expression and patient overall 
survival (Fig. 1H), using median of NTRK2 expression as a cutoff between low and high 
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expression. We further looked at the effect of NTRK2 expression in patients stratified by EGFR 
amplification (Fig. 1I). Survival of GBM patients was not significantly different when tumors with 
high and low NTRK2 expression levels were compared. 
 
 
Figure 1 should be inserted here 
 
 
Selective inhibition of TrkB and EGFR decreases GBM cell viability 
 
To examine the effects of TrkB and EGFR inhibition on cell viability, GBM cells were treated 
with ANA-12 and AG 1478 alone or in combination and viability was assessed by the trypan blue 
exclusion method. Time course analysis showed that both single treatments decreased A172 and 
U87MG cell viability when compared with control cells treated with vehicle (p < 0.001). The 
effect was observed in A172 cells after 48 hours of treatment with ANA-12 at 10 μM or AG1478 
at 30 μM (Fig. 2A, 2B). A similar effect was observed in U87MG cells after 24 hours of treatment 
with the dose of 10 μM of ANA-12 or AG1478 (Fig. 2C, 2D).  We also analyzed whether the 
reduction of cell viability with ANA-12 or AG1478 were dose-dependent. As depicted in Fig. 2, 
both treatments showed features of dose-dependent effect in A172 and U87MG cells. After time 
course and dose-response curves analysis, we defined proper doses and time to evaluate the effect 
of the combination (ANA-12 plus AG1478) on cell viability. When the two drugs were combined 
the inhibitory effect was more pronounced in A172 cells compared to either IC50-equivalent 
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isolated drugs and in the combination of both drugs in higher doses (see Fig. 2I for detailed results 
and p values for specific comparisons). In contrast, the effect of the combination treatment was 




Figure 2 should be inserted here 
 
 
Pharmacological interactions between TrkB and EGFR inhibitors 
 
In order to evaluate drug interaction effects, IC50-values were calculated from the effects seen in 
the cytotoxicity assay (Fig. 3). ANA-12 had IC50 values of 10.0 (7-14) μM and 13.85 (11-17) μM 
for A172 and U87MG cells, respectively. IC50 values of AG1478 were 20.0 (16-21) μM for A172 
cells and 13.26 (11-16) μM for U87MG cells (Fig. 3A). Pharmacological interactions of the 
combined treatment with ANA-12 and AG1478 were investigated using cytotoxicity as the chosen 
outcome and evaluated by Chou-Talalay method (Chou and Talalay 1984). Synergism, addition 
and antagonism for drug combinations was defined as CI < 0.9, CI = 0.9-1.1 and CI > 1.1, 
respectively.  We observed synergy in A172 cells (CI = 0.75). However, in U87MG cells the 








Figure 3 should be inserted here 
 
 
TrkB and EGFR inhibitors induce changes in cell cycle features of GBM cells 
 
Effects on cell cycle were evaluated by flow cytometry after treatment with ANA-12 and AG 1478 
alone or in combination in GBM cells. As shown in Fig. 4, the TrkB inhibitor induced a significant 
reduction in S phase, which starts at the dose of 10 μM and persists at a dose of 20 μM in A172 
cells (Fig. 4A p < 0.001 and p < 0.0001, respectively). An increase in cells in the S phase after 
TrkB inhibition was observed in U87MG cells at the dose of 50 μM (p < 0.05, Fig. 4D). Treatment 
with 30 μM of AG 1478 significantly increased the number of A172 and U87MG cells in G0/G1 
phase when compared with control cells (Fig. 4B, 4E, p < 0.01 and p < 0.05, respectively).  The 
combined treatment lead to a combination of effects leading to both accumulation of cells in G0/G1 
and reduction of S phase in A172 cells (Fig. 4C p < 0.05 and p < 0.01). The combined treatment 
did not cause significant changes in the cell cycle of U87MG cells; however, we could observe a 
small percentage of cells in Sub-G1 phase when compared with controls (Fig. 4F, p < 0.05). 
 
 





Long-term effects of TrkB and EGFR inhibition in a GBM xenograft mouse model 
 
To explore the roles of EGFR and TrkB during tumorigenesis, we used a preclinical subcutaneous 
xenograft GBM model. U87MG cells were treated with ANA-12, AG 1478, ANA-12 plus AG 
1478 and DMSO or EtOH. After 24 h, the animals were randomized and viable pre-treated U87MG 
cells were injected subcutaneously into the right flank of mice (Fig. 5A). Fig. 5B illustrates tumor 
volume size across different days. Tumor size was significantly different in day 15 in all treatment 
groups when compared with controls given vehicle. Mice that received cells treated with ANA-
12, alone or combined with AG 1478, also showed smaller tumors at day 31. The apparent 
reduction in tumor size in all drug-treated groups compared to controls at day 45 did not reach 
statistical significance (Fig. 5C). When tumors reached 800-100 mm3 the mice were euthanized, 
and the tumors were excised, and weight and volume were determined. Ex-vivo tumor analysis 
showed an apparent reduction in tumor volume when compared treatment groups with control, 
however, these differences did not reach statistical significance (Fig. 5D). Moreover, there were 
no statistically significant differences among groups regarding tumor weight (Fig. 5E). We also 
evaluated possible differences in survival comparing treatment groups with control group. 
Although the median survival days of the control group (38 days) was lower when compared to 
treatment groups (ANA-12, 45 days; AG 1478, 41 days; ANA-12+AG 1478, 44 days), no 









Figure 5 should be inserted here 
 
 
Lack of effect of combined TrkB and EGFR inhibition on intracranial GBM tumor 
growth 
 
We tested the hypothesis that the combined inhibition of TrkB plus EGFR would inhibit the growth 
of intracranial GBM in mice. Seven days after inoculation of U87MG cells, mice were randomized 
to receive i.p. injections in a period of 21 days with ANA-12 (1 mg/kg daily plus vehicle every 3 
days), AG1478 (10 mg/kg every three days plus vehicle daily), ANA-12 (1 mg/kg daily) plus AG 
1478 (10 mg/kg every three days) and vehicle daily. During the treatment period, mice were 
monitored daily for any signs of sickness, pain or weight loss. The tumor growth was analyzed by 
ex-vivo brain fluorescent imaging of the different groups using the IVIS system after 29 days after 
cell inoculation. Tumor fluorescence did not reveal a significant difference among groups (p = 




Gene expression analysis in GBM tumor datasets showed an increased NTRK2 expression in 
proneural, G-CIMP+ GBMs. Interestingly, significant correlations between NTRK2 and EGFR 
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expression levels were found in GBM, particularly in G-CIMP+ tumors. Previous analyses of 
TCGA GBMs have shown that G-CIMP+ glioblastomas presented reduced mRNA levels for 
EGFR due to epigenetic regulation [27]. The proneural G-CIMP phenotype confers a survival 
advantage for GBM patients [3], and its possible relationship with NTRK2 expression revealed 
here warrants further exploration. 
One of the main findings in the present study was that the combined inhibition of TrkB and 
EGFR was more pronounced than either treatment given alone in impairing A172 GBM cell 
viability. This result is consistent with the view that TrkB inhibition may sensitize cancer cells to 
the effects of EGFR inhibitors [28]. ANA-12, originally developed as an experimental 
antidepressant, selectively and efficiently inhibits TrkB by binding to both low- and high-affinity 
sites on the receptor extracellular domain [21]. AG 1478 is a selective EGFR inhibitor that shares 
a structural quinazoline main chain with the clinically used EGFR inhibitors gefitinib and erlotinib 
[20]. The results observed with these two small-molecule compounds in two different mouse GBM 
xenograft models were less clear. When cells were pretreated with drug treatments before being 
xenografted into the flanks of nude mice, treatments were able to slow tumor growth only at 
specific time points (15 and 31 days after cell inoculation), but drug-treated tumors were able to 
reach sizes comparable to controls by the end of the follow-up period. In addition, treatments did 
not significantly change tumor progression assessed by fluorescence in mice receiving GBM cells 
intracranially followed by systemic drug treatments. Given the potency of ANA-12 and AG1478 
inhibition of cell viability in vitro, we expected to observe pronounced drug effects in in vivo 
models. A possible limitation was measuring fluorescence only at the end of treatment rather than 
at different time points during treatment. Importantly, EGFR may have a dual role, contributing to 
tumor progression but also conferring increased DNA damage response and high sensitivity to the 
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inhibitor talazoparib [29]. Thus, differential roles of EGFR signaling could occur under the 
different experimental conditions we used (for example, regulation by the tumor 
microenvironment in in vivo assays), resulting in contrasting findings. The lack of effects may also 
be related to the choice of drug doses in our experiments. The drug doses and treatment regimens 
we used for in vivo experiments were based on previous studies that used xenograft models of 
GBM and other cancer types [22, 24, 25]. It is still possible that, as suggested by our results shown 
in Fig. 3, the two drugs used show antagonistic activity in U87MG cells. Another point worth 
mentioning is that, together, the results obtained in our in vitro and flank xenograft experiments 
might suggest that TrkB and EGFR inhibition can delay GBM growth in the short-term, but not 
after longer delays, when tumors are able to recover full growth. 
One issue worthy discussing is the opposite pattern of effects on cytotoxity between the 
two cell lines. Pharmacological interaction analysis showed synergism in A172 cells but 
antagonism in U87 MG cells. In terms of genetic profiles, both A172 and U87 MG cells are mutant 
for both CDKN2A and PTEN. However, U87 MG cells express only wild-type EGFR, whereas 
A172 cells also express TDM/18-26 mutant EGFR [30, 31]. This biological difference might be 
crucial to explain the contrasting effects we observed between cell lines. In addition, we have 
previously observed, in experiments using medulloblastoma cells, that BDNF/TrkB signaling may 
have opposite effects on cell viability, so TrkB activation can either induce or prevent cytotoxicity 
depending on drug combinations and experimental conditions [32 - 34]. In fact, BDNF can play 
opposite actions depending on changes in cellular context. These differential effects may involve 
distinct isoforms of TrkB expressed in different cell tumor types [34]. This dependency on cellular 
environment might also be related to the switch from synergism to antagonism we observed when 
TrkB inhibition was combined with EGFR inhibitor. GBM tumors interact in complex ways with 
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a microenvironment consisting of glial, endothelial, and immune cells. Several signaling 
molecules, including growth factors, mediate intercellular communication between GBM cells and 
cells composing the microenvironment [35 - 37]. It is thus possible that the interactions between 
receptors such as TrkB and EGFR in GBM, as well as the effects of receptor inhibitors, are 
modulated by biochemical signals from the microenvironment. It is also possible that inhibitors 
interact directly with receptors on cells in the microenvironment, resulting in changes of drug 
responses in vivo compared to in vitro models. These are complex issues that warrant further 
research in the field of targeted therapies for GBM.          
  GBM differentiated cells have been shown to secrete BDNF to stimulate TrkB in GBM 
stem cells and induce them to secrete nerve growth factor inducible (VGF), a neuropeptide that 
promotes survival and growth of GBM stem-like and differentiated cells [15]. TrkB knockdown 
or pharmacological inhibition of TrkB hinders BDNF-dependent GBM stem-like cell growth [13]. 
TrkB-containing exosomes promote the transfer of aggressiveness between GBM cells [38]. EGFR 
inhibition has been proposed as a therapeutic strategy in GBM and has been tested in preclinical 
[39 – 41] and clinical [42, 43] studies, with mixed results. One previous study examined the 
interaction between TrkB and EGFR in experimental GBM and showed that stimulation of 
neurotrophin signaling can overcome the inhibitory effects of EGFR inhibition on GBM cell 
growth [13]. The present study is the first one to verify whether the combined inhibition of TrkB 
and EGFR may effectively reduce GBM growth.      
In summary, analysis of TCGA tumors showed that correlations between NTRK2 and 
EGFR expression can be observed in GBM, and the role of TrkB and EGFR in the proneural, G-
CIMP+ subtype of GBM should be further investigated by future studies. In addition, our results 
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using cultured cells indicate for the first time the potential of combining TrkB and EGFR inhibition 
for the treatment of GBM, however we could not observe pronounced effects in vivo.     
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Legends for figures 
 
Fig 1 NTRK2 expression and its correlation with EGFR expression levels in TCGA GBM datasets. 
Transcript levels of NTRK2 were examined in previously described transcriptome datasets from 
the TCGA GBM dataset (n = 631 samples) and the TCGA Lower Grade Glioma (LGG) and GBM 
(n =702 samples) dataset. (A) Expression levels of NTRK2 in LGG and GBM patient cohorts. (B) 
Normal brain, primary and recurrent GBM samples. (C) GBM subtypes. (D) cytosine-phosphate-
guanine (CpG) island methylator phenotype (G-CIMP). Data was presented in violin plot format 
as log2-transformed signal intensity and statistical analyses were performed using Kruskal-Wallis 
test followed by Dunn’s post hoc tests, * p < 0.05; ** p < 0.01; *** p < 0.001 and **** p < 0.0001 
for significance. (E, F, G) Correlation between NTRK2 and EGFR expression levels in the TCGA 
GBM dataset. Pearson correlation coefficients and their p values were calculated using GraphPad 
prism. Trend lines were determined by the linear regression model. Overall survival probability in 
a set of 523 samples from the TCGA GBM cohort. (H) all samples and (I) EGFR amplified 
samples. Patients were grouped according to low or high expression of NTRK2. Survival 
distribution was estimated according to the Kaplan-Meier method using median cut-off selection 
and log-rank statistics. 
 
Fig 2 Inhibition of TrkB and EGFR alone or in combination reduces human GBM cell viability. 
Time course analysis of cell viability, by trypan blue cell counting, were performed after 24, 48 
and 72 h of exposure to ANA-12 or AG 1478 exposure in A172 (A, B) and U87MG (C, D) cells. 
Dose-response curves were evaluated by trypan blue cell counting after treatment with increasing 
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concentrations of ANA-12 (1-50 µM) or AG 1478 (1-30 µM) for 48 h in A172 cells (E, F) and 24 
h in U87MG cells (G, H). The drug vehicles (DMSO or EtOH) served as controls. Dose-response 
curves after combined treatment with ANA-12 and AG 1478 were evaluated after 48 h of drug 
exposure in A172 cells (I) and 24 h in U87MG cells (J). Data are expressed by mean ± SEM and 
represent three independent experiments *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
compared to control cells; # p < 0.05 and ### p < 0.001 compared to ANA-12; ++ p < 0.01 and 
+++ p < 0.001 compared with AG 1478; one-way ANOVA followed by Tukey tests for multiple 
comparisons). 
 
Fig 3 Synergistic effect after combined inhibition of TrkB and EGFR in A172 GBM cells. A172 
and U87MG cell lines were treated with varying concentrations of ANA-12 and AG 1478 alone 
or in combination. The IC50-values were calculated from the dose-response curves after different 
exposure times (48 h for A172 and 24 h for U87MG cells) and expressed with their respective 
95% confidence intervals and summarized in the table (A). The combination index (CI) was 
determined by the method of Chou-Talalay [20] and data are presented as mean ± SEM (B). 
 
Fig 4 Effects of EGRF and TrkB inhibition on GBM cell cycle. Cells were exposed to ANA-12, 
AG 1478 or ANA-12 plus AG 1478 for 24 h, and the percentages of cells in G0/G1, S and G2/M 
phases of the cell cycle were evaluated. Two wells were assigned to each treatment and the 
experiments were repeated at least three times. Data are presented as mean ± SEM of the 
percentage of cells in each phase. * p < 0.05; ** p < 0.01; *** p < 0.001 and **** p < 0.0001 




Fig 5 Inhibition of TrkB and EGFR alone or in combination in a subcutaneous GBM xenograft 
mouse model. U87MG cells were pretreated in vitro for 24 h with ANA-12 (13.85 μM), AG-1478 
(13.26 μM) or ANA-12 plus AG-1478, and the viable cells were injected into the flanks of nude 
mice (6-7 mice per group) as shown in the schematic drawing (A).  Caliper measurements were 
used to determine the displayed subcutaneous tumor volume. Mice were euthanized and tumors 
were excised when volume reached approximately 800-1,000 mm3 (B) Tumors were measured 
every 2 days and volumes were calculated as described in materials and methods section. Tumor 
growth is represented by tumor volume (mm3) at the indicated days; Control (n= 7), ANA-12 (n= 
8), AG 1478 (n= 8) and ANA-12 plus AG 1478 (n= 8) (C) Tumor growth curve is shown on 
selected time points of 15, 31 and 45 days to highlight statistical differences (D). Tumor volumes 
(mm3) at the time of tissue harvest. (E) Tumor weight (mg) at the time of tissue harvest are shown 
in (F) Kaplan-Meier curves presenting percent of mice surviving following tumor implantation. 
Data are expressed as mean ± SEM (* p < 0.05; ** p < 0.01). Statistical analysis was performed 
using one-way ANOVA followed by Tukey’s post-hoc tests. 
 
